Notably, genes of the SWItch/sucrose nonfermentable (SWI/SNF) chromatin remodeling complex are potential candidates for tissue-agnostic drug development, as these genes are commonly mutated in 20–25% of all human cancers [3]; this prevalence is notably higher than that of NTRK fusions (0.3%) [4]. Here, SMARCA1 is linked to cancer.